A recent study showcases the application of advanced AI-assisted molecular analysis to unravel how tuberculosis drugs kill bacteria, offering insights critical to developing faster and more effective treatment regimes. This approach addresses the complexity of TB’s drug resistance and long therapy durations. The technology promises to optimize drug combinations by precisely identifying mechanisms of action at a molecular level, potentially accelerating the end of TB treatment courses worldwide.